Diabetic Gastroparesis: Diagnosis, Management, and Future Perspectives
DOI:
https://doi.org/10.12775/QS.2024.19.53973Keywords
gastroparesis, diabetes mellitus, glycemic control, diet, scintigraphy, NaSSaS, metoclopramideAbstract
Gastroparesis, a complication of diabetes, is characterized by delayed gastric emptying without obstruction. It arises from chronic hyperglycemia-induced damage to the autonomic and enteric nervous systems, manifesting primarily as nausea, vomiting, early satiety, and bloating. This condition severely impacts quality of life and glycemic control, increasing the risk of further diabetes-related complications. Early diagnosis and treatment are essential, involving stringent glycemic control, lifestyle changes, pharmacological therapy, and sometimes surgical interventions. Diagnostic approaches include ruling out other causes, followed by tests like scintigraphy, radiological examination, and breath tests. Treatment begins with dietary modifications and, if necessary, progresses to enteral or parenteral nutrition. Glycemic management is crucial, with specific medications either recommended or contraindicated. Pharmacological treatments include metoclopramide and domperidone, though both have significant side effects. Emerging therapies involve ghrelin and motilin agonists, and antidepressants like mirtazapine. Gastric electrical stimulation, endoscopic, and surgical procedures offer additional treatment avenues for severe cases. Effective management of gastroparesis can substantially improve patient outcomes and long-term diabetes management.
References
Vanormelingen C, Tack J, Andrews CN. Diabetic gastroparesis. Br Med Bull. 2013;105:213-230. doi:10.1093/bmb/ldt003
Farmer AD, Bruckner-Holt C, Schwartz S, Sadler E, Kadirkamanthan S. Diabetic Gastroparesis: Perspectives From a Patient and Health Care Providers. J Patient Cent Res Rev. 2019;6(2):148-157. Published 2019 Apr 29. doi:10.17294/2330-0698.1689
Talley SJ, Bytzer P, Hammer J, Young L, Jones M, Horowitz M. Psychological distress is linked to gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol. 2001;96(4):1033-1038. doi:10.1111/j.1572-0241.2001.03605.x
Aswath GS, Foris LA, Ashwath AK, Patel K. Diabetic Gastroparesis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 27, 2023.
Kumar M, Chapman A, Javed S, Alam U, Malik RA, Azmi S. The Investigation and Treatment of Diabetic Gastroparesis. Clin Ther. 2018;40(6):850-861. doi:10.1016/j.clinthera.2018.04.012
Krzyżewska M, Maroszek P, Mrozikiewicz-Rakowska B, et al. Diabetic gastroparesis: do you know how to recognize and effectively treat? Clinical Diabetology. 2014;3: 157-166.
Bharucha AE, Kudva YC, Prichard DO. Diabetic Gastroparesis. Endocr Rev. 2019;40(5):1318-1352. doi:10.1210/er.2018-00161
Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol. 2008;36(1):44-54. doi:10.2967/jnmt.107.048116
Camilleri M, Iturrino J, Bharucha AE, et al. Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. Neurogastroenterol Motil. 2012;24(12):1076-e562. doi:10.1111/j.1365-2982.2012.01972.x
Desai A, O'Connor M, Neja B, et al. Reproducibility of gastric emptying assessed with scintigraphy in patients with upper GI symptoms. Neurogastroenterol Motil. 2018;30(10):e13365. doi:10.1111/nmo.13365
Parkman HP, Camilleri M, Farrugia G, et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol Motil. 2010;22(2):113-133. doi:10.1111/j.1365-2982.2009.01434.x
Waseem S, Moshiree B, Draganov PV. Gastroparesis: current diagnostic challenges and management considerations. World J Gastroenterol. 2009;15(1):25-37. doi:10.3748/wjg.15.25
Gharibans AA, Smarr BL, Kunkel DC, et al. Artifact Rejection Methodology Enables Continuous, Noninvasive Measurement of Gastric Myoelectric Activity in Ambulatory Subjects. Sci Rep. 2018;8: 5019. doi:10.1038/s41598-018-23302-9
Calder S, O'Grady G, Cheng LK, Peng Du. A Theoretical Analysis of Electrogastrography (EGG) Signatures Associated With Gastric Dysrhythmias. IEEE Trans Biomed Eng. 2017;64(7):1592-1601. doi:10.1109/TBME.2016.2614277
Levin AA, Levine MS, Rubesin SE, Laufer I. An 8-year review of barium studies in the diagnosis of gastroparesis. Clin Radiol. 2008;63(4):407-414. doi:10.1016/j.crad.2007.10.007
Parkman HP, Yates KP, Hasler WL, et al. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology. 2011;141(2):486-498.e4987. doi:10.1053/j.gastro.2011.04.045
Ogorek CP, Davidson L, Fisher RS, Krevsky B. Idiopathic gastroparesis is associated with a multiplicity of severe dietary deficiencies. Am J Gastroenterol. 1991;86(4):423-428.
Schweckendiek D, Pohl D. Pharmacologic treatment of gastroparesis: What is (still) on the horizon?. Curr Opin Pharmacol. 2023;72:102395. doi:10.1016/j.coph.2023.102395
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18-38. doi:10.1038/ajg.2012.373
Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol. 1996;91(10):2174-2178.
Schvarcz E, Palmér M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113(1):60-66. doi:10.1016/s0016-5085(97)70080-5
Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32(3):151-159. doi:10.1007/BF00265086
Aigner L, Becker B, Gerken S, Quast DR, Meier JJ, Nauck MA. Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes. Diabetes Care. 2021;44(2):479-488. doi:10.2337/dc20-1660
Holzäpfel A, Festa A, Stacher-Janotta G, et al. Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration. Diabetologia. 1999;42(12):1410-1412. doi:10.1007/s001250051311
Bharucha AE, Kudva Y, Basu A, et al. Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. Clin Gastroenterol Hepatol. 2015;13(3):466-476.e1. doi:10.1016/j.cgh.2014.06.034
Bharucha AE, Batey-Schaefer B, Cleary PA, et al. Delayed Gastric Emptying Is Associated With Early and Long-term Hyperglycemia in Type 1 Diabetes Mellitus. Gastroenterology. 2015;149(2):330-339. doi:10.1053/j.gastro.2015.05.007
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705. doi:10.1016/S0140-6736(06)69705-5
Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62(2):173-181. doi:10.1093/ajhp/62.2.173
Vella A, Lee JS, Camilleri M, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil. 2002;14(2):123-131. doi:10.1046/j.1365-2982.2002.00311.x
Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56(5):1475-1480. doi:10.2337/db07-0136
Young CF, Moussa M, Shubrook JH. Diabetic Gastroparesis: A Review [published correction appears in Diabetes Spectr. 2020 Nov;33(4):358. doi: 10.2337/ds20-er04]. Diabetes Spectr. 2020;33(3):290-297. doi:10.2337/ds19-0062
Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96(4):444-446. doi:10.7326/0003-4819-96-4-444
Lata PF, Pigarelli DL. Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother. 2003;37(1):122-126. doi:10.1345/aph.1C118
Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94(5):1230-1234. doi:10.1111/j.1572-0241.1999.00456.x
Shakhatreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol. 2019;13(8):711-721. doi:10.1080/17474124.2019.1645594
Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036-2045. doi:10.1111/j.1572-0241.2007.01255.x
Leelakanok N, Holcombe A, Schweizer ML. Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis. Clin Drug Investig. 2016;36(2):97-107. doi:10.1007/s40261-015-0360-0
Sanger GJ, Furness JB. Ghrelin and motilin receptors as drug targets for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2016;13(1):38-48. doi:10.1038/nrgastro.2015.163
Camilleri M. Gastrointestinal hormones and regulation of gastric emptying. Curr Opin Endocrinol Diabetes Obes. 2019;26(1):3-10. doi:10.1097/MED.0000000000000448
Hong SW, Chun J, Kim J, et al. Efficacy and Safety of Ghrelin Agonists in Patients with Diabetic Gastroparesis: A Systematic Review and Meta-Analysis. Gut Liver. 2020;14(5):589-600. doi:10.5009/gnl19103
Camilleri M, Lembo A, McCallum R, et al. Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. Aliment Pharmacol Ther. 2020;51(11):1139-1148. doi:10.1111/apt.15711
Nelson AD, Camilleri M, Acosta A, et al. Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. Neurogastroenterol Motil. 2016;28(11):1705-1713. doi:10.1111/nmo.12870
Malamood M, Roberts A, Kataria R, Parkman HP, Schey R. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017;11:1035-1041. Published 2017 Mar 30. doi:10.2147/DDDT.S125743
Marella HK, Saleem N, Olden K. Mirtazapine for Refractory Gastroparesis. ACG Case Rep J. 2019;6(10):e00256. Published 2019 Oct 22. doi:10.14309/crj.0000000000000256
Chu H, Lin Z, Zhong L, McCallum RW, Hou X. Treatment of high-frequency gastric electrical stimulation for gastroparesis. J Gastroenterol Hepatol. 2012;27(6):1017-1026. doi:10.1111/j.1440-1746.2011.06999.x
Shanker A, Bashashati M, Rezaie A. Gastric Electrical Stimulation for Treatment of Refractory Gastroparesis: the Current Approach to Management. Curr Gastroenterol Rep. 2021;23(2):2. Published 2021 Jan 22. doi:10.1007/s11894-020-00803-0
Wellington J, Scott B, Kundu S, Stuart P, Koch KL. Effect of endoscopic pyloric therapies for patients with nausea and vomiting and functional obstructive gastroparesis. Auton Neurosci. 2017;202:56-61. doi:10.1016/j.autneu.2016.07.004
Reichenbach ZW, Stanek S, Patel S, et al. Botulinum Toxin A Improves Symptoms of Gastroparesis. Dig Dis Sci. 2020;65(5):1396-1404. doi:10.1007/s10620-019-05885-z
Martinek J, Hustak R, Mares J, et al. Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial. Gut. 2022;71(11):2170-2178. doi:10.1136/gutjnl-2022-326904
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marcin Dołęga, Olgierd Dróżdż, Piotr Gacka, Dominika Musialska, Joanna Gołda, Julia Mężyk, Aleksandra Snopkowska

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 106
Number of citations: 0